FindTrial
Sign In

A PHASE II, MULTICENTER, UNCONTROLLED, OPEN STUDY IN PATIENTS WITH CHRONIC HEPATITIS C WHO ARE INTOLERANT TO INTERFERONS THERAPY TO EVALUATE THE SAFETY AND EFFICACY OF A TREATMENT WITH THYMOSIN ALPHA 1 PLUS RIBAVIRIN.

A PHASE II, MULTICENTER, UNCONTROLLED, OPEN STUDY IN PATIENTS WITH CHRONIC HEPATITIS C WHO ARE INTOLERANT TO INTERFERONS THERAPY TO EVALUATE THE SAFETY AND EFFICACY OF A TREATMENT WITH THYMOSIN ALPHA 1 PLUS RIBAVIRIN.

Status
Not yet recruiting
Phases
Unknown
Study type
Interventional
Source
EU CTR
Registry ID
EUCTR2004-001927-39-IT
Enrollment
Unknown
Registered
2005-03-04
Start date
2005-01-20
Completion date
Unknown
Last updated
2012-03-19

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

TREATMENT OF PATIENTS WITH CHRONIC HEPATITIS C WHO ARE INTOLERANT TO INTERFERONS THERAPY MedDRA version: 6.1 Level: PT Classification code 10019744

Interventions

Trade Name: ZADAXIN*INIETT. 1FL 1,6MG+1F Product Name: NA Product Code: NA Pharmaceutical Form: Powder and solvent for solution for injection INN or Proposed INN: VARI CAS Number: 62304-98-7 Concentra

Sponsors

SIGMA-TAU
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: Are the trial subjects under 18? no Number of subjects for this age range: F.1.2 Adults (18-64 years) yes F.1.2.1 Number of subjects for this age range F.1.3 Elderly (>=65 years) no F.1.3.1 Number of subjects for this age range

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

MeasureTime frame
Main Objective: ;Secondary Objective: ;Primary end point(s):—

Countries

Italy

Outcome results

None listed

Source: EU CTR (via WHO ICTRP) · Data processed: Feb 4, 2026